AbbVie Free Cash Flow 2010-2024 | ABBV
AbbVie annual/quarterly free cash flow history and growth rate from 2010 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
- AbbVie free cash flow for the quarter ending September 30, 2024 was 11,075.00, a year-over-year.
- AbbVie free cash flow for the twelve months ending September 30, 2024 was , a year-over-year.
- AbbVie annual free cash flow for 2023 was $22.062B, a 9.02% decline from 2022.
- AbbVie annual free cash flow for 2022 was $24.248B, a 10.27% increase from 2021.
- AbbVie annual free cash flow for 2021 was $21.99B, a 30.97% increase from 2020.
| AbbVie Annual Free Cash Flow |
| 2023 |
22,062.00 |
| 2022 |
24,248.00 |
| 2021 |
21,990.00 |
| 2020 |
16,790.00 |
| 2019 |
12,772.00 |
| 2018 |
12,789.00 |
| 2017 |
9,431.00 |
| 2016 |
6,562.00 |
| 2015 |
7,003.00 |
| 2014 |
2,937.00 |
| 2013 |
5,776.00 |
| 2012 |
6,012.00 |
| 2011 |
5,891.00 |
| 2010 |
4,528.00 |
| 2009 |
5,054.77 |
| AbbVie Quarterly Free Cash Flow |
| 2024-09-30 |
11,075.00 |
| 2024-06-30 |
5,877.00 |
| 2024-03-31 |
3,847.00 |
| 2023-12-31 |
22,062.00 |
| 2023-09-30 |
17,514.00 |
| 2023-06-30 |
10,159.00 |
| 2023-03-31 |
4,018.00 |
| 2022-12-31 |
24,248.00 |
| 2022-09-30 |
17,033.00 |
| 2022-06-30 |
9,608.00 |
| 2022-03-31 |
4,746.00 |
| 2021-12-31 |
21,990.00 |
| 2021-09-30 |
17,102.00 |
| 2021-06-30 |
9,384.00 |
| 2021-03-31 |
4,689.00 |
| 2020-12-31 |
16,790.00 |
| 2020-09-30 |
12,215.00 |
| 2020-06-30 |
6,602.00 |
| 2020-03-31 |
3,690.00 |
| 2019-12-31 |
12,772.00 |
| 2019-09-30 |
9,660.00 |
| 2019-06-30 |
5,259.00 |
| 2019-03-31 |
2,910.00 |
| 2018-12-31 |
12,789.00 |
| 2018-09-30 |
9,520.00 |
| 2018-06-30 |
5,278.00 |
| 2018-03-31 |
2,526.00 |
| 2017-12-31 |
9,431.00 |
| 2017-09-30 |
7,029.00 |
| 2017-06-30 |
3,884.00 |
| 2017-03-31 |
2,007.00 |
| 2016-12-31 |
6,562.00 |
| 2016-09-30 |
5,135.00 |
| 2016-06-30 |
3,794.00 |
| 2016-03-31 |
2,007.00 |
| 2015-12-31 |
7,003.00 |
| 2015-09-30 |
5,185.00 |
| 2015-06-30 |
3,157.00 |
| 2015-03-31 |
1,440.00 |
| 2014-12-31 |
2,937.00 |
| 2014-09-30 |
3,668.00 |
| 2014-06-30 |
2,062.00 |
| 2014-03-31 |
487.00 |
| 2013-12-31 |
5,776.00 |
| 2013-09-30 |
4,682.00 |
| 2013-06-30 |
3,017.00 |
| 2013-03-31 |
1,099.00 |
| 2012-12-31 |
6,012.00 |
| 2012-09-30 |
5,166.00 |
| 2012-06-30 |
2,899.00 |
| 2012-03-31 |
1,432.00 |
| 2011-12-31 |
5,891.45 |
| 2011-09-30 |
4,947.09 |
| 2011-06-30 |
3,240.84 |
| 2011-03-31 |
1,184.87 |
| 2010-12-31 |
|
| 2009-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$318.085B |
$54.318B |
|
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
|
